AstraZeneca reports boost in cancer drug sales

LONDON — Anglo-Swedish drugmaker AstraZeneca is reporting its first quarterly sales in years on the back of new cancer treatments.

The company said Friday that product sales rose 4 percent in the fourth quarter to $5.49 billion, buoyed by new drugs such as bladder cancer treatment Imfinzi, and lymphoma medication Calquence.

It was the first increase since the third quarter of 2014.

AstraZeneca says it expects product sales to increase "in the low single digits" this year.

Despite encouraging news on the sales front, net income fell 29 percent to $1.3 billion. Core operating profit, which excludes restructuring and acquisition-related costs to give a better picture of underlying performance, fell 12 percent to $1.79 billion.

CEO Pascal Soriot says the sales increase shows AstraZeneca is "steadily turning a corner."

You may also interested in

China imports grow in August for 1st time in 2...

Sep 8, 2016

China trade showed unexpected strength in August in a positive sign for global economic growth

Aid groups warn of crisis as Mongolia hit by...

Dec 21, 2016

Another unusually harsh winter in Mongolia that's decimating livestock and sending temperatures to...

Asian stocks markets retreat after Wall Street...

Dec 23, 2016

Most Asian stock markets have declined in thin trading ahead of the Christmas holiday after Wall...

DEA opens shop in China to help fight synthetic...

Jan 6, 2017

The U.S. Drug Enforcement Administration plans to open a new office in southern China and, at...

Chinese delegation open to meeting Trump's team...

Jan 11, 2017

A Chinese official says President Xi Jinping's delegation to the World Economic Forum is open to...

About Us

Frontal Report is an emerging leader in all forms of media. We aim to be the leading news brand for readers around the world.

Contact us: sales[at]frontalreport.com

Subscribe Now!